Develop New Therapies Articles & Analysis
293 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective ...
With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. Ace Therapeutics Psychiatry Team is committed to supporting scientists in making ...
Protheragen’s diagnostic development services aim to fill the gaps in research, facilitating new insights and breakthroughs in the understanding of these diseases. ...
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. Despite extensive research, translating findings from bench to bedside remains a challenge. Precision Cut Lung Slices (PCLS) have emerged as a versatile tool in COPD research, offering unique advantages for understanding disease mechanisms and ...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. ...
It primarily serves researchers with its state-of-the-art facilities and experienced team, which specializes in the synthesis and development of a broad range of drug conjugates. By leveraging their vast expertise in active pharmaceutical ingredient (API) binding technologies, CD Formulation facilitates the production of new chemical entities (NCEs) that are ...
With extensive experience in the antipsychiatry industry, the Ace Therapeutics Psychiatry team understands the unique challenges and complexities of developing effective therapies for psychiatric disorders. By leveraging its expertise and resources, the company can develop animal models, cell models, multicellular models, ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...
“The new drug development services focus on the hotspot of pancreatic tumor. ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
The availability of recombinant human collagen COL4 opens up new opportunities for researchers and clinicians in studying and developing therapies for diseases related to basement membrane dysfunction. Alfa Chemistry prides itself on providing high-quality recombinant human collagen products that meet the rigorous standards of research and ...
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. ...
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that ...
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research. This path-breaking move sees the integration of cutting-edge technology with state-of-art research facilities to amplify the possibilities of devising effective remedies for rare diseases. Rare ...
Our experienced team of CAR-T specialists can not only develop cutting-edge CAR-T therapies using advanced technologies, but also perform related biochemical evaluations." In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of ...
CD Genomics' HLA typing solutions integrate advanced NGS technologies, setting new standards for accuracy and reliability. Leveraging the power of NGS, their solutions offer unparalleled precision, empowering researchers and clinicians to uncover the most intricate HLA allele combinations with utmost confidence. ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence. Hervé has more than 25 years of experience in sales, business ...
Meanwhile, for healiva®002, we will improve the product, scale up the manufacturing process, and continue its clinical development for future commercial success at scale.” Among the populations that may particularly benefit from these new treatments are: The elderly: 2–3% of whom have venous/arterial leg ulcers. ...
.* Further information can be found at Celiacshield.com. * The content of this news release is solely the responsibility of ImmunogenX and does not necessarily represent the official views of the National Institutes of Health. About ImmunogenX ImmunogenX, Inc. is a clinical-stage biopharmaceutical company founded in 2013 and is supported by a team of world-renowned clinicians, ...